Skip to content
Screener

Scholar Rock SRRK Q2 2026 earnings

Reported August 6, 2026 · Before market open

Revenue-
EPS-$0.84Beat by $0.00
EPS estimate-$0.84
“We are on the threshold of securing the world's first ever regulatory approval of a myostatin inhibitor, which will also be the first ever muscle-targeted treatment for children and adults living with SMA. Backed by a strong balance sheet, our Scholar Rock team is ready to usher in the next phase of innovation for the SMA community in the U.S. immediately upon apitegromab approval.”
David L. Hallal

Next report

Nov 13, 2026 (in 2 months)
Revenue estimate$732.5K
EPS estimate-$0.86

Financials

Q2 2026

Income statement

See full
Revenue-—
Operating income-$108.9M+2.9%
Net income-$109.9M+0.1%
EPS (diluted)-$0.84+14.3%

Balance sheet

See full
Cash & equivalents$437.1M+186%
Total debt$203.8M+231%
Total equity$253.8M+8.8%
Total assets$523.5M+54.0%

Cash flow

See full
Operating cash flow-$70.3M+8.6%
CapEx$1.0K-99.5%
Free cash flow-$70.3M+8.9%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$6.01B+95.8%
Enterprise value$5.78B+93.9%

Returns & leverage

See full
Return on equity-167.8%-4.1pp
Debt / equity0.8×+0.5×
Current ratio7×+0.7×

FAQ

When did Scholar Rock report Q2 2026 earnings?
Scholar Rock (SRRK) reported Q2 2026 earnings on August 6, 2026 before market open.
What were Scholar Rock's Q2 2026 revenue and EPS?
Scholar Rock reported revenue of - and eps of $-0.84 for Q2 2026.
Did Scholar Rock beat estimates in Q2 2026?
EPS beat the consensus estimate of $-0.84 by $0.00.
How did Scholar Rock's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 14.3% from $-0.98.
Where can I find Scholar Rock's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-336715) and the 10-Q periodic report (0001193125-26-336732) directly on SEC EDGAR. The filing index links above go to sec.gov.